TAIP.Y Stock Overview
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Taisho Pharmaceutical Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.00 |
| 52 Week High | US$15.52 |
| 52 Week Low | US$8.88 |
| Beta | 0.44 |
| 1 Month Change | -7.12% |
| 3 Month Change | -10.10% |
| 1 Year Change | 22.53% |
| 3 Year Change | -16.45% |
| 5 Year Change | -43.00% |
| Change since IPO | -32.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| TAIP.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.4% | -2.2% | -3.7% |
| 1Y | 22.5% | 11.6% | 20.5% |
Return vs Industry: TAIP.Y exceeded the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: TAIP.Y exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| TAIP.Y volatility | |
|---|---|
| TAIP.Y Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TAIP.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: TAIP.Y's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 8,784 | Akira Uehara | www.taisho-holdings.co.jp |
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The company offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops.
Taisho Pharmaceutical Holdings Co., Ltd. Fundamentals Summary
| TAIP.Y fundamental statistics | |
|---|---|
| Market cap | US$4.26b |
| Earnings (TTM) | US$54.46m |
| Revenue (TTM) | US$2.07b |
78.3x
P/E Ratio2.1x
P/S RatioIs TAIP.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TAIP.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥320.39b |
| Cost of Revenue | JP¥137.22b |
| Gross Profit | JP¥183.17b |
| Other Expenses | JP¥174.74b |
| Earnings | JP¥8.42b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 25.68 |
| Gross Margin | 57.17% |
| Net Profit Margin | 2.63% |
| Debt/Equity Ratio | 0% |
How did TAIP.Y perform over the long term?
See historical performance and comparison